Harvard Bioscience vs 908 Devices
HBIO and MASS side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HBIO and MASS compare
908 Devices is the larger company, worth 9.4 times as much as Harvard Bioscience ($403M against $42.7M).
908 Devices grew revenue faster over the last twelve months (23.7% versus 2.3% for Harvard Bioscience).
Harvard Bioscience keeps more of each dollar of sales as profit, with a net margin of −13.2% compared with −36.9% at 908 Devices.
908 Devices scores higher on the StockData Score (11 against 3 for Harvard Bioscience), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HBIO | MASS |
|---|---|---|
| Size and price | ||
| Market cap | $42.7M | $403M |
| Share price | $9.39 | $9.74 |
| Change, 1 year | 50.9% | 65.1% |
| Change, 5 years | −87.4% | −62.4% |
| Beta (5Y) | 1.39 | 1.70 |
| Employees | 339 | 172 |
| StockData Score | ||
| Total score | 3 | 11 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 3 (better) |
| Performance score | 1 | 1 |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.5× (better) | 6.1× |
| P/B | 8.4× | 2.7× (better) |
| P/FCF | – | 153× |
| FCF yield | −7.4% | 0.65% (better) |
| Fair value | – | $7.62 |
| Margin of safety | – | −27.8% |
| Growth | ||
| Revenue growth (TTM) | 2.3% | 23.7% (better) |
| Revenue growth, 5Y average | −3.3% | 15.9% (better) |
| Profitability | ||
| Gross margin | 57.4% (better) | 52.3% |
| Operating margin | −1.8% (better) | −42.7% |
| Net margin | −13.2% (better) | −36.9% |
| FCF margin | −3.5% | 4.0% (better) |
| Return on equity | −123% | −17.0% (better) |
| Return on invested capital | −5.6% (better) | −59.2% |
| Financial health | ||
| Debt / equity | 7.28 (better) | 0.00 |
| Current ratio | 1.76 | 5.43 (better) |
| Altman Z-score | −2.36 | 3.64 (better) |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 36.9% | 70.2% |
| Held by insiders | – | 21.0% |
| Insider net buying, 12 months | $202K (better) | −$10.3M |
| Short interest, % of float | – | 7.8% |
Go deeper
- HBIO stock overview
- HBIO income statement
- HBIO valuation and score
- MASS stock overview
- MASS income statement
- MASS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.